The following criteria is provided for health care professionals.

Inclusion Criteria

• Evidence of disease progression:
  • Symptomatic relapsed or refractory requiring current treatment.
  • Previously treated with ≥ 3 prior regimens (lines of therapy) that included at least one of each of the following: alkylating agent, immunomodulatory drug, proteasome inhibitor, and a steroid.
  • Must be refractory to most recent anti-cancer regimen.
• Must have measurable disease defined by one of the following:
  • Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or for IgA myeloma, by quantitative IgA; or
  • Urinary M-protein excretion at least 200 mg/24 hours; or
  • Serum Free Light Chain (Serum FLC) whereby the involved light chain measures ≥ 10 mg/dL and with an abnormal ratio.
• Eastern Cooperative Oncology Group performance status of ≤ 1.

Exclusion Criteria

• Time since the last prior therapy:
  • Radiation, chemotherapy, immunotherapy or any other anticancer therapy, including investigational anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1.
  • Palliative steroids for disease related symptoms are allowed up to 3 days prior to Cycle 1 Day 1.
• Active graft versus host disease after allogeneic stem cell transplantation. At least 3 months must have elapsed since completion of allogeneic stem cell transplantation.
• Active central nervous system malignancy. Patients who have only had prophylactic intrathecal or intravenous chemotherapy against central nervous system disease are eligible.
• Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT-8602.
• Prior exposure to a SINE compound.